Healthcare
DBV Technologies SA(DBVT)
Live Price
Offline$15.70
+1.09% today
1Y Change
+81.71%
Window
Jun 25, 2025 → Jun 22, 2026
- Market Cap
- $710.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -41.7%
- Dividend Yield
- 0.0%
Coverage: 248 bars · Jun 25, 2025 → Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
DBV Technologies SA (DBVT) is a Healthcare stock with a market cap of $710.00M and listed on NASDAQ. The stock last traded around $15.70 and up 81.7% across the available one-year price window (Jun 25, 2025 → Jun 22, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -41.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -41.7%, free cash flow -13.4% with operating margin -20017.3% and ROIC -77.0%. Valuation already assumes a fairly strong business story at price/sales 947.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines DBVT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-20017.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -41.7%, with operating margin around -20017.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Δ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | — | +3.4% | -1.0% | -6.5% |
2026 Mar 26, 2026 | +11.5% | -1.0% | +4.2% | -2.0% |
2025 Oct 28, 2025 | +17.2% | -2.2% | -7.7% | -16.7% |
Benchmark Edge
DBVT vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DBVT
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DBVT Max Drawdown
-36.72%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DBVT and SPY.
Company Overview
DBV Technologies SA
NASDAQ
DBV Technologies is a clinical-stage biopharmaceutical company headquartered in Bagneux, France, specializing in immunotherapy treatments for food allergies. The company is known for developing the Viaskin patch, a proprietary transdermal technology designed to administer allergens to intact skin while preventing transfer to the bloodstream. DBV Technologies' primary focus is addressing peanut allergies and cow's milk allergies in pediatric populations, conditions for which limited effective treatment options currently exist. The company's lead candidates include Viaskin Peanut, which aims to help patients tolerate peanut exposure and reduce the risk of severe allergic reactions from accidental exposure, and Viaskin Milk for milk allergy treatment. Viaskin Peanut has received Fast Track designation from the US Food and Drug Administration, reflecting its potential significance in addressing unmet medical needs. Additionally, DBV Technologies developed the E-patch, a standardized diagnostic tool for identifying allergies in children. Founded in 2002, the company operates as a publicly traded biopharmaceutical firm focused on transforming treatment approaches within the immunotherapy field.
- Leadership
- Mr. Daniel Tassé
- Employees
- 117
- Street Address
- Bâtiment IRO, 107 Av. de la REpublique
- Mailing
- Châtillon, 92320
- Region
- Châtillon, France
- Last Updated
- May 15, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 947.8
- Price/Book
- 4.8
Growth
- Revenue
- 0.0%
- EPS
- -41.7%
- Free Cash Flow
- -13.4%
Profitability
- Gross Margin
- -1042.6%
- Operating Margin
- -20017.3%
- Net Margin
- -19549.8%
- ROE
- -189.5%
- ROIC
- -77.0%
Balance Sheet
- Debt/Equity
- 0.13
- Current Ratio
- 3.67
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.